Healix Infusion Therapy Selected as Limited Distribution Network Partner for Cutaquig®


Healix Infusion Therapy Selected as Limited Distribution Network Partner for Cutaquig®, Octapharma’s new 16.5% Subcutaneous Immune Globulin.

SUGAR LAND, TX ( May 29, 2019) – Healix Infusion Therapy is pleased to announce that it has been selected as a limited distribution network partner for Cutaquig by Octapharma AG. Cutaquig, Octapharma’s new subcutaneous immune globulin, launches this week. “We are excited to partner with Octapharma as they launch Cutaquig, especially given the critical shortage of other immunoglobulin products in the market,” said Greg Mitchell, Executive Vice President at Healix. “Our large initial purchase of Cutaquig, which will be housed in our new 10,000 square foot distribution center, allows us to commit to supplying our patients and physicians with the immune globulin products they need.”

Healix employs a team of pharmacists who focus on intravenous and subcutaneous immune globulin therapy. “Our specialized pharmacists and clinical teams consult with our physicians regarding the appropriate therapy for each patient,” said Lucinda Van Anglen, Senior Vice President of Pharmacy at Healix. “Our high-touch model ensures that patients receive the medication, training, and support they need to properly manage their health. We are excited to add Cutaquig to our list of preferred medications.”

To learn more about partnering with Healix to gain access to Cutaquig please contact Healix at 1.866.654.2451 or [email protected].

About Healix

Healix is the nation’s leader in providing physician office-based infusion services with more than 225 infusion sites around the country. Focused on patient and physician peace of mind for 30 years, we offer unparalleled capabilities for optimal patient care, comfort, compliance, and clinical outcomes in an outpatient setting. To learn more, visit www.healix.net.

About Cutaquig

Cutaquig (Immune Globulin Subcutaneous (Human) – hipp), is a 16.5% immune globulin solution for subcutaneous infusion indicated for treatment of primary humoral immunodeficiency (PI) in adults. If you would like more information about Cutaquig, please contact Octapharma USA Customer Service at 866-766-4860, or [email protected].

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.